royalty-free voluntary licencing agreements with Gilead Sciences Ireland UC to manufacture and distribute the latter's human immunodeficiency virus (HIV) drug Lenacapavir in India and 120 low- and ...

Gilead forecasts it will generate between $28.2 billion and $28.6 billion in full-year sales in 2025. The company didn't reveal how the lenacapavir PrEP rollout will play into that total number ...

Peter Wickersham is the Vice President and General Manager of Gilead Sciences UK & Ireland, and a leader in HIV treatment, liver disease, and oncology. With over 25 years in healthcare ...

Gilead Sciences' ascent to the upper echelon of biotech centered around one very savvy acquisition that launched an HIV franchise. Shortly after the turn of the century, Gilead Sciences took a ...